ArticlePLoS medicine2015
Paying physicians to prescribe generic drugs and follow-on biologics in the United States.
Article in PLoS medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Association Between Patient Sociodemographic Characteristics and Generic Drug Use: A Systematic Review and Meta-analysis.Journal of managed care & specialty pharmacy · 2018Pooled it
- Article
- Article
- Sub-Standard Pharmaceutical Services in Private Healthcare Facilities Serving Low-Income Settlements in Nairobi County, Kenya.Pharmacy (Basel, Switzerland) · 2019Article
- Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications.Journal of clinical pharmacy and therapeutics · 2018Article
- Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.BMJ (Clinical research ed.) · 2018Observational
- Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.The Milbank quarterly · 2017Article
- Active Surveillance of Follow-on Biologics: A Prescription for Uptake.Drug safety · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aaron Kesselheim and colleagues examine potential strategies to promote greater prescribing of generic drugs and follow-on biologics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.